Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35503   clinical trials with a EudraCT protocol, of which   5838   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-001858-41
    Sponsor's Protocol Code Number:D5082C00002
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-02-24
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-001858-41
    A.3Full title of the trial
    A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
    Un ensayo de fase II para evaluar la eficacia de AZD6094 (HMPL-504) en pacientes con carcinoma papilar de células renales (PRCC, por sus siglas en inglés).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    This is a study designed to evaluate the effectiveness and safety of AZD6094 in patients with Papillary Renal Cell Cancer.
    Este estudio ha sido diseñado para evaluar la efectividad y seguridad de AZD6094 en pacientes con carcinoma papilar de células renales.
    A.3.2Name or abbreviated title of the trial where available
    A Phase II Trial to Evaluate the Efficacy of AZD6094 in Patients With PRCC
    Un ensayo defase II para evaluar la eficacia de AZD6094 en pacientes con PRCC
    A.4.1Sponsor's protocol code numberD5082C00002
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02127710
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstra Zeneca AB
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstra Zeneca AB
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca AB
    B.5.2Functional name of contact pointClinical Trial Transparency
    B.5.3 Address:
    B.5.3.1Street AddressAstraZeneca, Poland Sp. Z o. o., ul. Woloska 5
    B.5.3.2Town/ cityWarsaw
    B.5.3.3Post code02-676
    B.5.3.4CountryPoland
    B.5.6E-mailClinicalTrialTransparency@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code AZD6094, HMPL-504
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSavolitinib (proposed INN)
    D.3.9.1CAS number 1313725-88-0
    D.3.9.2Current sponsor codeAZD6094, HMPL-504
    D.3.9.3Other descriptive nameVolitinib (Chinese approved name)
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code AZD6094, HMPL-504
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSavolitinib (proposed INN)
    D.3.9.1CAS number 1313725-88-0
    D.3.9.2Current sponsor codeAZD6094, HMPL-504
    D.3.9.3Other descriptive nameVolitinib (Chinese approved name)
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Papillary Renal Cell Carcinoma (PRCC)
    Carcinoma papilar de células renales (PRCC, por sus siglas en inglés).
    E.1.1.1Medical condition in easily understood language
    Renal Cell Cancer
    Carcinoma de células renales.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Assess the anti-tumour activity of AZD6094 in patients with papillary renal cell carcinoma (PRCC) as measured by investigator-assessment of overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
    Evaluar la actividad anti-tumoral del AZD6094 en pacientes con carcinoma papilar de células renales (PRCC, por sus siglas en inglés), según la medición de la evaluación de la tasa de respuesta general (ORR, por sus siglas en inglés) realizada por el investigador de acuerdo con los Criterios de Evaluación de Respuesta en Tumores Sólidos (RECIST, por sus siglas en inglés) v1.1.
    E.2.2Secondary objectives of the trial
    Assess progression free survival. Assess the safety and tolerability of AZD 6094. Safety profiles will be assessed in terms of AEs and laboratory data, vital signs and ECGs that will be collected for all patients. Pharmacokinetics (PK) of AZD6094 and major metabolites M2 and M3 for AUC, AUC(0-24), AUC(0-t), AUCss, Cmax, Css max, and Css min. Characterise the pharmacokinetics (PK) of AZD6094 and the major metabolites M2 and M3 following administration to steady state after multiple dosing when given orally. Assess change in target lesion tumor size from baseline. Change in Target Lesion is percentage change from baseline in tumor size at 12 weeks. Assess duration of response according to RECIST v1.1. Assess duration of overall survival according to RECIST v1.1.
    Evaluar la supervivencia libre de progresión (PFS, por sus siglas en inglés), el cambio en el tamaño del tumor determinado como la lesión seleccionada en comparación con la línea de base, duración de la respuesta (DoR, por sus siglas en inglés) y supervivencia general (OS, por sus siglas en inglés) en pacientes con PRCC de acuerdo con RECIST v1.1.
    Evaluar la seguridad y tolerabilidad del AZD6094 en el tratamiento de pacientes con PRCC.
    Caracterizar la farmacocinética (PK, por sus siglas en inglés) del AZD6094 y los principales metabolitos M2 y M3 después de la administración hasta el estado estacionario después de múltiples dosis administradas oralmente.
    Obtener una evaluación preliminar de la actividad tumoral del AZD6094 por medio de la evaluación de los cambios en biomarcadores farmacodinámicos (PDc, por sus siglas en inglés), incluyendo c-Met total y c-Met fosforilado.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Provision of informed consent prior to any study specific procedures, sampling and analyses.
    Histologically confirmed papillary renal cell cancer, which is locally advanced
    Availability of an archival tumor sample or a pre-treatment fresh tumor sample for confirmation of PRCC by a central laboratory and other biomarker
    Treatment naïve or previously treated PRCC.
    Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    At least one lesion, not previously irradiated, and not chosen for a biopsy if performed during the screening period that can be accurately measured at baseline and which is suitable for accurate repeated measurements.
    Adequate hematological function defined as:
    a.(ANC) > or = 1500/dL
    b.(Hgb) > or = 9 g/dL
    c.Platelets > or = 100,000/µL
    Adequate liver function defined as:
    a.(ALT) and (AST) < or = 2.5 xthe upper limit of normal (ULN)
    b.Total bilirubin < or = 1.5 x ULN
    Adequate renal function defined as glomerular filtration rate (GFR) > or = 40 mL/min,
    Adequate coagulation parameters, defined as International Normalisation Ratio(INR) <1.5 x ULN or activated partial thromboplastin time (aPTT) <1.5 x ULN.
    Patients with known tumor thrombus or deep vein thrombosis (DVT) are eligible if stable on low molecular weight heparin (LMWH) for > or = 2 weeks.
    Females should be using adequate contraceptive measures should notbe breast feeding, and must have a negative pregnancy test prior to start of dosing ifof childbearing potential or must have evidence of non-childbearing potential
    Male patients should be willing to use barrier contraception, i.e. condoms.
    Ability to swallow and retain oral medications.
    Predicted life expectancy > or = 12 weeks.
    Aged at least 18 years.
    Willingness and ability to comply with study and follow-up procedures.
    Ability to understand the nature of this study and give written informed consent.
    Suministro de un consentimiento informado antes de cualquier procedimiento, recogida de muestra y análisis específicos del estudio.
    Cáncer papilar de células renales histológicamente confirmado, que sea metastásico o localmente avanzado.
    Disponibilidad de una muestra de tumor de archivo o muestra de tumor nueva previa al tratamiento para confirmación del PRCC por un laboratorio central y otros biomarcadores.
    PRCC con o sin tratamiento previo.
    Estado de desarrollo de Eastern Cooperative Oncology Group (ECOG) de 0 o 1.
    Por lo menos una lesión, sin irradiación previa, y no elegida para una biopsia si se realizó durante el período de selección, que se pueda medir con precisión en la línea de base y que sea apta para mediciones precisas repetidas.
    Función hematológica adecuada definida de la siguiente manera:
    - Recuento de neutrófilos absolutos (ANC, por sus siglas en inglés) > o = 1500/dL
    - Hemoglobina (Hgb) > o = 9 g/dL
    - Plaquetas > o = 100,000/µL
    Función hepática adecuada definida de la siguiente manera:
    - Aminotransferasa alanina (ALT) y aspartato aminotransferasa (AST) < o = 2.5 x el límite superior de normal (ULN, por su sigla en inglés)
    - Bilirrubina total < o = 1.5 x ULN
    Función renal adecuada definida como tasa de filtración glomerular (GFR, por sus siglas en inglés) > o = 40 mL/min.
    Parámetros de coagulación adecuados, definidos como Relación de Normalización Internacional (INR) <1.5 x ULN o tiempo de tromboplastina parcial activada (aPTT) <1.5 x ULN.
    Los pacientes con trombo de tumor o trombosis venosa profunda (DVT, por sus siglas en inglés) conocidos son elegibles si se encuentran estables tomando heparina de bajo peso molecular (LMWH, por su sigla en inglés) durante > o = 2 semanas.
    Las mujeres deben estar utilizando medidas anticonceptivas adecuadas, no deben estar amamantando y deben tener un resultado negativo en una prueba de embarazo antes de comenzar a recibir las dosis si son fértiles, o deben probar no ser fértiles
    Los pacientes del sexo masculino deben estar dispuestos a utilizar métodos anticonceptivos de barrera como, por ejemplo, preservativos.
    Capacidad de tragar y retener medicamentos orales.
    Expectativa de vida prevista > o = 12 semanas.
    Tener por lo menos 18 años de edad.
    Disposición y capacidad de cumplir con el estudio y los procedimientos de seguimiento.
    Capacidad de comprender la naturaleza de este estudio y de dar su consentimiento informado por escrito.
    E.4Principal exclusion criteria
    Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents <21 days of the first dose of study treatment. Most recent targeted therapy <14 days of the first dose of study treatment.
    Unresolved toxicities from any prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the exception of alopecia.
    Prior or current treatment with a cMet inhibitor (e.g. Foretinib, Crizotinib, Cabozantinib, Onartuzumab). Patients with limited exposure may be discussed with
    the study medical monitor.
    Strong inducers or inhibitors of CYP3A4 or strong inhibitors of CYP1A2 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
    Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered < or = 28 days or limited field radiation for palliation < or = 7 days prior to starting study drug or has not recovered from side effects of such therapy
    Major surgical procedures < or = 28 days of beginning study drug or minor surgical procedures < or = 7 days. No waiting is required following port-a-cath placement.
    Previously untreated brain metastases.
    Current leptomeningeal metastases or spinal cord compression due to disease.
    Acute or chronic liver or pancreatic disease.
    Uncontrolled diabetes mellitus.
    Gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy
    Any of the following cardiac diseases currently or within the last 6 months:
    a.Unstable angina pectoris
    b.Congestive heart failure (New York Heart Association [NYHA] > or = Grade 2
    c.Acute myocardial infarction
    d.Stroke or transient ischemic attack
    Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] >160 mmHg or diastolic blood pressure (DBP) >100 mmHg) (patients with values above these levels must have their blood pressure (BP) controlled with medication prior to starting treatment).
    Mean resting correct QT interval (QTc) >470 msec obtained from triplicate ECGs.
    Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiograms (ECGs), e.g. complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec.
    Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital or familial long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medications known to prolong QT interval.
    Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin (LMWH) is allowed.
    Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
    Known diagnosis of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
    Presence of other active cancers, or history of treatment for invasive cancer < or = 5years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
    Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
    Agentes de quimioterapia, inmunot., quimioinmunot. o de investigación más recientes a <21 días de la primera dosis del tto. del estudio. Terapia dirigida más reciente a <14 días de la primera dosis del tto. del estudio.
    Toxicidades sin resolver de cualquier terapia anterior superior a los Criterios de Terminología Común para Eventos Adversos (CTCAE) Grado 1 al iniciar el tto. del estudio, con excepción de alopecia.
    Tto. actual o anterior con inhibidor de c-Met Fuertes inductores o inhibidores de CYP3A4 o fuertes inhib. de CYP1A2 en 2 semanas anteriores a la primera dosis del tto. del estudio (3 sem. para Hierba de S. Juan) Apéndice I.
    Radioterapia de campo extendido (incluye radioisótopos terapéuticos, tales como estroncio 89) adm. < o = 28 días o radiación de campo limitado para paliación < o = 7 días antes de comenzar a tomar el medicam.del estudio o que no se haya recuperado de los efectos secundarios de dicha terapia.
    Procedim. quirúrgicos mayores < o = 28 días antes de comenzar a tomar el medicam. del estudio o proced. quirúrgicos menores < o = 7 días antes. No se requiere espera después de la colocación de un catéter Port-a-Cath.
    Metástasis cerebral sin tto. anterior.
    Más recientes agentes de quimiot., inmunoter., quimioinmunot. o de investigación a <21 días de la primera dosis del tto. del estudio. Terapia dirigida más reciente a <14 días de la primera dosis del tto. del estudio.
    Toxicidades sin resolver de cualquier terapia anterior superior a los Criterios de Terminología Común para Eventos Adversos (CTCAE) Grado 1 al iniciar el tto. del estudio, con excepción de alopecia.
    Tto. actual o anterior con inhib. de c-Met (por ej. Foretinib, crizotinib, Cabozantinib, Onartuzumab). Los pac. con exposición limitada pueden ser discutidos por el monitor médico estudio.
    Fuertes inductores o inhib. de CYP3A4 o fuertes inhib. de CYP1A2 en las 2 semanas anteriores a la primera dosis del tto. del estudio (3 semanas para Hierba de San Juan) Apéndice I.
    Radioterapia de campo extendido (incluye radioisótopos terapéuticos, tales como estroncio 89) adm. < o = 28 días o radiación de campo limitado para paliación < o = 7 días antes de comenzar a tomar el medicam. del estudio o que no se haya recuperado de los ef. secundarios de dicha terapia.
    Proced. quirúrgicos mayores < o = 28 días antes de comenzar a tomar el medicam. del estudio o procedim. quirúrgicos menores < o = 7 días antes. No se requiere espera después de la colocación de un catéter Port-a-Cath.
    Metástasis cerebral sin tto. anterior.
    Metástasis leptomeníngea actual o compresión en la médula espinal debido a la enferm.
    Enferm. hepática o pancreática aguda o crónica.
    Diabetes mellitus no controlada.
    Enferm. gastrointestinal u otra afección que interferirá significat.en la absorción, distrib., el metabolismo o la excreción de terapia oral.
    Cualquiera de las siguientes enferm. cardíacas, actualmente o en los últimos 6 meses:
    Angina de pecho inestable
    Insuficiencia cardíaca congestiva (New York Heart Association [NYHA] > o = Grado 2 [Apéndice H])
    Infarto de miocardio agudo
    Derrame cerebral o accidente isquémico transitorio
    Hipertensión sin control adecuado (o sea, presión sanguínea sistólica [SBP] >160 mmHg o presión sanguínea diastólica (DBP) >100 mmHg) (los pac. con valores superiores a estos niveles deben controlar su presión sanguínea (BP, por sus siglas en inglés) con medicación antes de comenzar el tto.).
    Intervalo QT correcto medio (QTc) en reposo >470 mseg obtenido a partir de ECGs por triplicado.
    Cualq. anormalidad clínicam. imp. en el ritmo, la conducción o la morfología de electrocard. (ECGs) en reposo; por ej., bloqueo completo de rama izq., bloqueo cardíaco de tercer grado, bloqueo card. de segundo grado, intervalo de PR >250 mseg.
    Cualq. factor que incremente el riesgo de prolong. de QTc o riesgo de eventos arrítmicos tales como insuf. cardíaca, hipocaliemia, síndrome de QT largo congénito o familiar o muerte súbita sin explicación en menores de 40 años de edad o cualquier medicam. concomitante conocido para prolongar el intervalo QT.
    Recibe actualmente tto. con dosis terapéuticas de sodio de warfarina. Se permite heparina de bajo peso molecular (LMWH, por su sigla en inglés).
    Infección activa grave al momento del tto., o cualquier otra afección médica subyacente que podría afectar la capacidad del pac. de recibir el tto. del protocolo.
    Diagnóstico conocido de virus de inmunodeficiencia humana (VIH), hepatitis B o hepatitis C.
    Presencia de otros cánceres activos, u historial de tto. para cáncer invasivo < o = 5 años. Los pac. con cáncer de Etapa I que recibieron tto. local definitivo como mínimo 3 años antes y en los que se considere improbable la recurrencia, son elegibles. Todos los pac. con carcinoma in situ previamente tratado (o sea, no invasivo) son elegibles, así como pac. con historial de cáncer de piel no melanoma.
    Cond. psicológicas, familiares, sociológicas o geográficas que no permitan cumplir el protoc.
    E.5 End points
    E.5.1Primary end point(s)
    Objective tumour response (confirmed PR or CR) as assessed by RECIST v1.1.
    Respuesta objetiva del tumor (PR o CR confirmados), según evaluación por medio de RECIST v1.1.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline to Week 12
    Desde el inicio hasta la semana 12
    E.5.2Secondary end point(s)
    Week 12 and best percentage change from baseline in target lesion tumour size.
    Time-to-event endpoints: e.g., PFS, DoR and OS.
    PK parameters including AUC, Cmax, Tmax, Vz/F, CL/F, t½?z, and MRT.
    PDc assessments c total cMet-and phosphorylated-cMet.
    Safety and tolerability (as adverse events are characterised and graded by National Cancer Institute Common Terminology Criteria for Adverse Event [NCI CTCAE] v4.03).
    Cambio en Semana 12 y mejor porcentaje a partir de la línea de base en el tamaño del tumor definido como lesión seleccionada.
    Criterios de valoración tiempo a evento: o sea, PFS, DoR y OS.
    Parámetros PK, que incluyen AUC, Cmax, Tmax, Vz/F, CL/F, t½?z y MRT.
    Evaluaciones PDc - c-Met total y c-Met fosforilado.
    Seguridad y tolerabilidad (según caracterización y calificación de eventos adversos de los Criterios de Terminología Común para Eventos Adversos del Instituto Nacional del Cáncer [NCI CTCAE] v4.03).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Baseline to Week 12
    Desde el inicio hasta la semana 12
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA20
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    France
    Germany
    Italy
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLVS
    Última visita del último paciente.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 50
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 25
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 37
    F.4.2.2In the whole clinical trial 75
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects randomized to AZD6094 may continue to receive AZD6094 as
    long as they are continuing to show clinical benefit, as judged by the
    investigator, and in the absence of discontinuation criteria.
    Los pacientes pueden seguir recibiendo AZD6094 más allá de la progresión definida en RECIST v1.1 siempre y cuando sigan exhibiendo beneficios clínicos, según criterio del Investigador.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-04-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-04-09
    P. End of Trial
    P.End of Trial StatusCompleted
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA